HEALTHWTOP DC
Louisiana’s abortion drug access law heightens hemorrhage risk for pregnant patients
Louisiana's 2024 law reclassified misoprostol as a controlled substance, requiring it to be stored securely and delaying access during emergencies. This has increased hemorrhage risks for pregnant patients, as misoprostol is a critical, cost-effective drug for treating postpartum hemorrhage and has other reproductive healthcare uses.
Mentioned
Related Signal
Adjacent reporting
- Louisiana’s abortion drug access law heightens hemorrhage risk for pregnant patients
- Miscarriage patients have fewer treatment options in states with abortion bans, study shows
- So Much for Leaving Abortion Up to the States
- Louisiana women face healthcare crisis after abortion ban
- Abortion medication, HPV vaccine laws take effect today in three states
- Miscarriage patients have fewer treatment options in states with abortion bans, study shows